Fresh off positive results for its late-stage lung drug, InterMune has attracted some M&A interest from a flock of pharmaceutical companies, according to Reuters, sending the biotech's shares up roughly 12% on Friday.
Biomet, a maker of medical devices based in Warsaw, IN, has reportedly filed with U.S. regulators for an IPO nominally valued at $100 million.
INC Research is doubling down on the Middle East, buying up a longtime partner to tighten its grip on a region the CRO says is rapidly developing into a go-to market for clinical research.
Roche's debt from its 2009 buyout of Genentech is winding down--and less money to pay means more money to play with, outgoing chairman Franz Humer says.
With his nearly 20-year stint at Roche coming to an end, longtime Roche Chairman Franz Humer said he's leaving the drugmaker just as it gets out from under Genentech-related debt, clearing the way for some dealmaking and an R&D jump-start.
Novartis Chairman Joerg Reinhardt may be chatting with his colleagues at Roche. His company may want to work more closely with its hometown rival. But joining forces in a merger? No, thank you.
Indian CRO GVK Biosciences has become a global player since Sequoia Capital first bought a stake back in 2007, and now the venture capital stalwart is looking to sell its share at more than three times the price, according to The Economic Times.
Endo Health Solutions ended 2013 very much a company in transition. The Pennsylvania device and pharmaceutical operation experienced a fourth-quarter sales drop and sizeable net losses, but those results stemmed, in part, from the sale of one division and costs related to an M&A deal.
Given Imaging's time as an independent company has come to a close. As expected, Irish medical device giant Covidien ($COV) has closed its $860 million buyout of the Israeli company known for its endoscopic PillCam capsules.
Bayer already has a big footprint in China, where it's been selling drugs since the 1930s. But that footprint is about to get a bit bigger. The company is set to buy out China's Dihon Pharmaceutical Group, a company that specializes in OTC drugs--making it just the kind of pickup the German drugmaker's been scouting for.